A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

Clinically Isolated Syndrome Clinical Trial

— CIS-ON  

Official title:

A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebif®) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00287079
• Other study ID #: IMP 26222
• Status: Completed
• Phase: Phase 3
• First received: February 2, 2006
• Last updated: December 2, 2013
• Start date: October 2005
• Est. completion date: November 2008

Study information

• Verified date: December 2013
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second exacerbation - over 96 weeks in subjects that present with Clinically Isolated Syndrome (CIS) accompanied by an abnormal magnetic resonance imaging (MRI). The secondary objectives are to:

• Assess the effectiveness of sc IFN beta - 1a (Rebif®) therapy in reducing the proportion of patients with CIS converting to CDMS

• Assess the safety of sc IFN beta - 1a (Rebif®) in the patients with CIS

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: November 2008
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Months to 65 Years

Eligibility

Inclusion Criteria:

• Subject must have experienced a first clinical episode suggestive of demyelinating disease

• Subject must present with an abnormal MRI displaying at least 3 T2 weighted hyperintense lesions typical of multiple sclerosis (MS)

• Subject must be greater than or equal to 18 years old

• Subject must have had onset of the clinical attack within the last 120 days

• Subject must give written informed consent

• Female subjects must be neither pregnant nor breast feeding, and must not be of child-bearing potential as defined by either:

• Being post-menopausal or surgically sterile

• Using hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study

Subjects electing treatment:

• Subject must be eligible for Interferon-beta 1-a therapy

Exclusion Criteria:

• Subject has evidence of other neurological diseases that could explain his/her symptomatology

• Subject is pregnant or in lactation

• Subject suffers from an intercurrent autoimmune disease

• Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the procedures required by this study

• Subject has received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, campath), within 12 months of study day 1

Subjects electing treatment:

• Subject has inadequate liver function, defined by total bilirubin, aspartate transaminase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal values

• Subject has inadequate bone marrow reserve, defined as white blood cell count less than 0.5 times the lower limit of normal

• Subject has a known allergy to IFN or any of the excipients of the drug product

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Clinically Isolated Syndrome
• Syndrome

Intervention

Drug:
• Rebif®
44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks

Other:
• No Treatment
No treatment for 96 weeks

Locations

Country	Name	City	State
Canada	Canadian Medical Information Office	Windsor, Barrie, Hamilton, Mississauga	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Merck KGaA	EMD Serono Canada Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time in Month to Clinical Definite Multiple Sclerosis (CDMS) From Kaplan-Meier Estimates	CDMS was defined by the occurrence of a second exacerbation or relapse over 96 weeks in participants who presented with Clinically Isolated Syndrome (CIS) accompanied by an abnormal Magnetic Resonance Imaging (MRI) scan. Time was calculated from the date of the stabilization of the baseline CIS episode to the qualifying relapse for the CDMS.	Up to Week 96	No
Secondary	Percentage of Participants Who Converted to Clinical Definite Multiple Sclerosis (CDMS)	CDMS was defined as the occurrence of a second exacerbation over 96 weeks in participants who presented with CIS accompanied by an abnormal MRI scan.	Up to Week 96	Yes
Secondary	Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)	AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.	Up to Week 96	Yes

External Links

•   Full FDA approved prescribing information can be found here